Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
McCormick's Near-Term Catalyst Path is Choppy, UBS Says

McCormick's Near-Term Catalyst Path is Choppy, UBS Says

MT newswireMT newswire2026/10/02 15:27
11:27 AM EDT, 10/02/2026 (MT Newswires) -- McCormick's (MKC) near-term catalyst path is choppy as demand trends are yet to show meaningful signs of improvement amid concerns around cost inflation and the pending Unilever (UL) Foods transaction, UBS said in a research report emailed Friday. McCormick's Q3 results exceeded Wall Street's expectations, with adjusted EPS of $0.86, up from $0.85 a year earlier. Net sales for the quarter ended Aug. 31 were $2.02 billion, up from $1.72 billion a year earlier. With fiscal Q4 guidance indicating sustained volume pressure, UBS said it now expects a gradual improvement in consumer demand into fiscal 2027, driven by innovation, brand investment, and distribution gains. Cost initiatives and modest volume leverage should partly offset pressure below the gross profit line, UBS said, adding that it expects fiscal 2027 EPS of $3.13. The brokerage said it reiterated its neutral rating on the stock and lowered its price target to $48 per share from $52. Price: 44.25, Change: +0.11, Percent Change: +0.25
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks

Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.

智通财经•2026/10/26 03:41
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks